Jenthera

Jenthera Therapeutics is a preclinical biotechnology company that has developed a proprietary, non-viral, and non-lipid CRISPR platform designed for in vivo targeted gene editing. By directly delivering CRISPR ribonucleoproteins, the technology eliminates the need for adeno-associated viruses or nanoparticles, which are often limited by targeting range, safety concerns, or manufacturing complexity. The platform features a plug-and-play system that allows for precise, cell-specific delivery via intravenous administration. It supports various gene-editing applications, including knock-outs, knock-ins, and complex genetic manipulations, while maintaining an optimal safety profile regarding off-target incidence and immunogenicity.

The company focuses primarily on oncology, with current programs targeting indications such as B-cell lymphoma and non-small cell lung cancer. Their approach aims to overcome traditional barriers in gene therapy, such as reaching undruggable targets like KRAS and facilitating in vivo CAR-T reprogramming. By utilizing well-established biologic manufacturing processes, Jenthera seeks to provide high-quality, cost-effective therapeutic interventions. Headquartered in Montreal, Canada, the company operates as a research-driven organization aimed at developing next-generation gene editing therapies through both internal pipelines and strategic partnerships.